Key Highlights
- Hims & Hers Health (NYSE:HIMS) fell 16.61% on Tuesday, November 10, 2026, to about USD 19.16, extending its post-earnings slide after third-quarter results.
- Revenue rose 49% to USD 890.4 million, but the company swung to a net loss and subscribers fell sequentially to 2.79 million.
- Full-year 2026 adjusted EBITDA guidance was cut to USD 257 million to USD 277 million, its third reduction this year, from USD 300 million to USD 375 million set in February.
- Fourth-quarter Revenue guidance of USD 875 million to USD 895 million came in weaker than investors expected, and a Federal Trade Commission lawsuit has been joined by five states.
What Disappointed Investors
The subscriber decline was the biggest concern. Hims & Hers lost about 103,000 subscribers in the quarter, its first sequential decline in at least four years, although the total was still 13% higher than a year earlier. Recurring subscriptions are the foundation of the company's growth story and of the premium valuation investors have paid. Management attributed the decline partly to a deliberate pullback in Marketing ahead of new platform launches in the fourth quarter, saying it was intentionally pacing spending. Third-quarter revenue and adjusted EBITDA both came in below consensus, in part because some weight-loss revenue was deferred. The company swung to a net loss of USD 33.0 million, or USD 0.14 per share. Gross Margin fell to 57% from 74% a year earlier, because weight-loss products cost more to source and deliver than the hair, skin and sexual health products on which the Business was built. The shares had already dropped 11.77% on November 9.
Where Growth Is Coming From
Much of the revenue growth came from acquisitions and new markets. Eucalyptus, an Australian online health company acquired in June 2026, contributed about 46% of the year-on-year revenue increase. International revenue jumped 321% to USD 233.3 million, while US revenue grew 21% to USD 657.1 million. Monthly revenue per subscriber rose 30% to USD 105 as customers moved toward higher-priced weight-loss treatments. The company shifted its US weight-loss offering toward branded GLP-1 drugs and agreed to offer Lilly's Zepbound from USD 299 a month on a self-pay basis. Those products bring higher revenue per customer but lower margins, which explains why profit guidance fell even as sales grew. Investors now question whether the growth from acquisitions can be sustained once those deals are fully reflected in prior-year comparisons, and whether the company can return to subscriber growth while absorbing that margin pressure, especially as large pharmacies and drugmakers sell weight-loss drugs directly to consumers.
Regulatory and Balance Sheet Risks
A lawsuit filed by the Federal Trade Commission in July, now joined by five states, adds legal risk; the company has accrued about USD 60 million and a hearing is set for January 14, 2027. Hims & Hers also carries about USD 1.37 billion of convertible notes. Competition in direct-to-consumer telehealth is intense, and pricing for GLP-1 treatments continues to fall. Free Cash Flow dropped to USD 26.0 million in the quarter from USD 79.4 million a year earlier, and Operating Cash Flow was supported by the sale of receivables, which limits flexibility. The stock is popular with retail investors and heavily traded, which tends to magnify moves around results.
Where Things Stand
Hims & Hers faces a test of whether its fourth-quarter platform launches can restore subscriber growth and stabilise margins. Investors will watch subscriber trends, progress in branded weight-loss offerings, international growth and developments in the FTC case, with the January hearing and fourth-quarter results in February as the next major checkpoints. A return to sequential subscriber growth would be the clearest sign that the business has stabilised after the guidance cut.






Please wait processing your request...